Am I Eligible?

You may qualify for the AIRFLOW-3 Clinical Trial if:

- You have COPD and are taking daily medications to manage your symptoms
- Your COPD symptoms bother you frequently
- You have been hospitalized or have taken additional medications because of COPD flare-ups in the past year
- You are between 40 and 75 years old
- You are not currently a smoker, and will not start smoking again

For additional eligibility requirements and information, contact a study representative or visit www.airflowtrial.com

Are frequent COPD flare-ups keeping you down?

To learn more about the COPD lung intervention clinical study, go to www.airflowtrial.com or contact a study representative at:

NUVAIRA™

CE
2797

MCA-0031

Are frequent COPD flare-ups keeping you down?

You may qualify for a new COPD clinical study

AIRFLOW 3
CLINICAL TRIAL

About the Therapy

Patients with COPD have overactive nerves in their airways which contribute to symptoms and flare-ups (exacerbations) that may be mild, moderate or severe. While medications can help control COPD, drug therapy cannot effectively control flare-ups for some patients.

The AIRFLOW-3 Clinical Trial is using the Nuvaira™ Lung Denervation System, an investigational device in North America and a CE marked device in Europe, in a procedure called Targeted Lung Denervation, or TLD. The purpose of the AIRFLOW-3 Clinical Trial is to evaluate the safety and efficacy of TLD and the cost of COPD care in a portion of COPD patients. TLD is designed to reduce airway nerve activity which may help reduce the occurrence and/or severity of COPD flare-ups.

The TLD procedure:

- Non-surgical and takes about one hour
- Performed in a hospital under general sedation (patients are asleep during the procedure)
- Most patients return home the next day

What happens the day of the procedure?

Your medical team will:

- Give you medicines (sedation) so you sleep through the procedure
- Pass a standard bronchoscope through your mouth to a treatment location in the main airway of each of your lungs
- Inflate a specialized catheter which will keep your airways cool while the treatment energy is delivered to the nerves on the outside of your airways



Narrowed airway before TLD



Opened airway after TLD

Half of the patients will be randomly assigned to receive TLD treatment. TLD patients will have energy delivered to the nerves lining their airways. Patients randomly assigned to the non-treatment (“sham”) group will not receive energy to their lungs, but will be given the option to be treated after one year of follow up.

What are the costs and time commitments required for the study?

All study-related costs will be paid for by the study sponsor, and travel expenses may be reimbursed. Participation in the trial will be for 5 years and involves:

- Initial hospital screening tests and procedures
- Monthly phone contacts and five office visits during the first year after the procedure
- A 12-month visit, after which you will be informed whether you were in the TLD or sham group. Patients in the sham group will be given the option of receiving the TLD treatment at no cost.
- Follow-up office visits or calls approximately every six months

What are the potential benefits and risks?

While there are no guaranteed benefits, patients receiving TLD treatment may experience fewer or less severe COPD symptoms and flare-ups. Your participation may also help advance treatment for other patients in the future. As with any new treatment, not all the benefits and risks are known at this time.